Načítá se...
The clinical profile of benralizumab in the management of severe eosinophilic asthma
Despite several therapeutic choices, 10–20% of patients with severe uncontrolled asthma do not respond to maximal best standard treatments, leading to a healthcare expenditure of up to 80% of overall costs for asthma. Today, there are new important therapeutic strategies, both pharmacological and in...
Uloženo v:
| Vydáno v: | Ther Adv Respir Dis |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5933597/ https://ncbi.nlm.nih.gov/pubmed/27612492 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753465816667659 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|